139 related articles for article (PubMed ID: 1906055)
1. Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genes.
Ostrand-Rosenberg S; Roby C; Clements VK; Cole GA
Int J Cancer Suppl; 1991; 6():61-8. PubMed ID: 1906055
[TBL] [Abstract][Full Text] [Related]
2. Rejection of mouse sarcoma cells after transfection of MHC class II genes.
Ostrand-Rosenberg S; Thakur A; Clements V
J Immunol; 1990 May; 144(10):4068-71. PubMed ID: 2332639
[TBL] [Abstract][Full Text] [Related]
3. Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule.
Ostrand-Rosenberg S; Roby CA; Clements VK
J Immunol; 1991 Oct; 147(7):2419-22. PubMed ID: 1918972
[TBL] [Abstract][Full Text] [Related]
4. Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.
Ostrand-Rosenberg S; Baskar S; Patterson N; Clements VK
Tissue Antigens; 1996 May; 47(5):414-21. PubMed ID: 8795142
[TBL] [Abstract][Full Text] [Related]
5. Transfection of major histocompatibility complex class I and class II genes causes tumour rejection.
Ostrand-Rosenberg S; Clements VK; Thakur A; Cole GA
J Immunogenet; 1989; 16(4-5):343-9. PubMed ID: 2639907
[TBL] [Abstract][Full Text] [Related]
6. Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity.
Baskar S; Nabavi N; Glimcher LH; Ostrand-Rosenberg S
J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):209-15. PubMed ID: 8297902
[TBL] [Abstract][Full Text] [Related]
7. MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice.
Baskar S; Azarenko V; Garcia Marshall E; Hughes E; Ostrand-Rosenberg S
Cell Immunol; 1994 Apr; 155(1):123-33. PubMed ID: 8168141
[TBL] [Abstract][Full Text] [Related]
8. Fibrosarcoma cells expressing allogeneic MHC Class II antigens induce protective antitumor immunity.
Leach DR; Callahan GN
J Immunol; 1995 Jan; 154(2):738-43. PubMed ID: 7814880
[TBL] [Abstract][Full Text] [Related]
9. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
Baskar S; Clements VK; Glimcher LH; Nabavi N; Ostrand-Rosenberg S
J Immunol; 1996 May; 156(10):3821-7. PubMed ID: 8621919
[TBL] [Abstract][Full Text] [Related]
10. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
Chen PW; Ananthaswamy HN
J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
[TBL] [Abstract][Full Text] [Related]
11. Invariant chain alters the malignant phenotype of MHC class II+ tumor cells.
Clements VK; Baskar S; Armstrong TD; Ostrand-Rosenberg S
J Immunol; 1992 Oct; 149(7):2391-6. PubMed ID: 1527384
[TBL] [Abstract][Full Text] [Related]
12. Single amino acid mutations in the murine MHC class II A beta cytoplasmic domain abrogate antigen presentation.
Laufer TM; Smiley ST; Ranger A; Clements VK; Ostrand-Rosenberg S; Glimcher LH
J Immunol; 1997 Dec; 159(12):5914-20. PubMed ID: 9550388
[TBL] [Abstract][Full Text] [Related]
13. Transfection and expression of syngeneic H-2 genes does not reduce malignancy of H-2 negative teratocarcinoma cells in the autologous host.
Ostrand-Rosenberg S; Cole GA; Nishimura MI; Clements VK
Cell Immunol; 1990 Jun; 128(1):152-64. PubMed ID: 2344619
[TBL] [Abstract][Full Text] [Related]
14. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.
Baskar S; Ostrand-Rosenberg S; Nabavi N; Nadler LM; Freeman GJ; Glimcher LH
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5687-90. PubMed ID: 7685909
[TBL] [Abstract][Full Text] [Related]
15. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
[TBL] [Abstract][Full Text] [Related]
16. Rejection of allogeneic and syngeneic but not MHC class I-deficient tumor grafts by MHC class I-deficient mice.
Freland S; Chambers BJ; Andersson M; Van Kaer L; Ljunggren HG
J Immunol; 1998 Jan; 160(2):572-9. PubMed ID: 9551890
[TBL] [Abstract][Full Text] [Related]
17. MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes.
Armstrong TD; Clements VK; Ostrand-Rosenberg S
J Immunol; 1998 Jan; 160(2):661-6. PubMed ID: 9551900
[TBL] [Abstract][Full Text] [Related]
18. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.
Armstrong TD; Clements VK; Martin BK; Ting JP; Ostrand-Rosenberg S
Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6886-91. PubMed ID: 9192661
[TBL] [Abstract][Full Text] [Related]
19. Rejection of allogeneic tumor is not determined by host responses to MHC class I molecules and is mediated by CD4-CD8+ T lymphocytes that are not lytic for the tumor.
Cole GA; Ostrand-Rosenberg S
Cell Immunol; 1991 May; 134(2):480-90. PubMed ID: 1902400
[TBL] [Abstract][Full Text] [Related]
20. Generation of an antitumour immune response to a murine mesothelioma cell line by the transfection of allogeneic MHC genes.
Leong CC; Robinson BW; Garlepp MJ
Int J Cancer; 1994 Oct; 59(2):212-6. PubMed ID: 7927922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
